Reaction from the field
The emergence of the cicada covid variant, officially designated as BA.3.2, has sent ripples of concern throughout the United States and beyond. This highly mutated variant, first identified in South Africa in November 2024, has been detected in at least 25 states as of February 11, 2026. With its 70 to 75 mutations in the spike protein, BA.3.2 may have the ability to evade immunity gained from vaccinations or previous infections, raising the stakes for public health.
Health experts are closely monitoring BA.3.2, which was classified as a ‘variant under monitoring’ by the World Health Organization (WHO) in December 2025. The variant’s rapid spread has been alarming, with reports indicating its presence in at least 23 countries since its initial detection. As of late March 2026, wastewater samples have shown that 11% contained traces of BA.3.2, highlighting its growing prevalence.
Common symptoms associated with BA.3.2 include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms mirror those of earlier COVID-19 variants, yet the potential for BA.3.2 to present a different challenge to the immune system cannot be overlooked. Dr. Andrew Pekosz, a prominent virologist, emphasized that “it has a lot of mutations that may cause it to look different to your immune system,” which could complicate the fight against the virus.
Despite these concerns, some experts urge caution. Dr. Adolfo García-Sastre noted that there is currently “no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This sentiment is echoed by Dr. Amesh A. Adalja, who reassured the public that “the existing vaccine is likely to protect against what matters most: serious illness.” Furthermore, Dr. Adalja stated, “There is no major reason for concern at this point,” suggesting that while vigilance is necessary, panic may not be warranted.
However, uncertainties loom large. The exact impact of BA.3.2 on disease severity remains unclear, and it is uncertain how effective current vaccines will be against this variant. The reasons for BA.3.2’s resurfacing are not fully understood, leaving health officials and the public with many questions. As the situation evolves, details remain unconfirmed, and ongoing research will be crucial in determining the best course of action.
As the cicada covid variant continues to spread, public health officials are urging individuals to remain vigilant. Vaccination remains a key defense against severe illness, and health authorities are likely to adapt their strategies in response to the evolving landscape of COVID-19 variants. The emergence of BA.3.2 serves as a reminder of the virus’s unpredictable nature and the importance of continued monitoring and research.
In the coming weeks and months, further developments are expected as scientists and health organizations work to understand the implications of BA.3.2 fully. The public is encouraged to stay informed and follow guidance from health authorities to mitigate the impact of this new variant. As we navigate this ongoing pandemic, the resilience of communities and the dedication of healthcare professionals will be vital in overcoming the challenges posed by the cicada covid variant.
You may also like
